atl iii Search Results


atl iii  (AbMole Bioscience)
90
AbMole Bioscience atl iii
<t>ATL</t> <t>III</t> attenuates esophageal injury in RE rats A) Images show the esophagus of rats after RE establishment and ATL III treatment in samples of a) sham group, b) RE group, c) ATL III (0.6 mg/kg), d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. B) H&E stained images of the sectioned esophagus tissues of rats after RE establishment and ATL III treatment. a) sham group, b) RE group, c) ATL III (0.6 mg/kg) d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after RE establishment and ATL III treatment. D) The graph indicates the gastric pH changes after RE establishment and ATL III treatment. *** indicates P < 0.001 vs. RE group. E) The graphs present the ROS and F) TBARS levels after various treatments of ATL-III group. *** indicates P < 0.001 vs. RE group .
Atl Iii, supplied by AbMole Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/atl+iii/pmc10632696-33-0-8?v=AbMole+Bioscience
Average 90 stars, based on 1 article reviews
atl iii - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
atl-iii  (FUJIFILM)
90
FUJIFILM atl-iii
<t>ATL</t> <t>III</t> attenuates esophageal injury in RE rats A) Images show the esophagus of rats after RE establishment and ATL III treatment in samples of a) sham group, b) RE group, c) ATL III (0.6 mg/kg), d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. B) H&E stained images of the sectioned esophagus tissues of rats after RE establishment and ATL III treatment. a) sham group, b) RE group, c) ATL III (0.6 mg/kg) d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after RE establishment and ATL III treatment. D) The graph indicates the gastric pH changes after RE establishment and ATL III treatment. *** indicates P < 0.001 vs. RE group. E) The graphs present the ROS and F) TBARS levels after various treatments of ATL-III group. *** indicates P < 0.001 vs. RE group .
Atl Iii, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/atl+iii/pm21130827-31-0-4?v=FUJIFILM
Average 90 stars, based on 1 article reviews
atl-iii - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


ATL III attenuates esophageal injury in RE rats A) Images show the esophagus of rats after RE establishment and ATL III treatment in samples of a) sham group, b) RE group, c) ATL III (0.6 mg/kg), d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. B) H&E stained images of the sectioned esophagus tissues of rats after RE establishment and ATL III treatment. a) sham group, b) RE group, c) ATL III (0.6 mg/kg) d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after RE establishment and ATL III treatment. D) The graph indicates the gastric pH changes after RE establishment and ATL III treatment. *** indicates P < 0.001 vs. RE group. E) The graphs present the ROS and F) TBARS levels after various treatments of ATL-III group. *** indicates P < 0.001 vs. RE group .

Journal: Heliyon

Article Title: Atractylenolide III ameliorated reflux esophagitis via PI3K/AKT/NF-κB/iNOS pathway in rats

doi: 10.1016/j.heliyon.2023.e21224

Figure Lengend Snippet: ATL III attenuates esophageal injury in RE rats A) Images show the esophagus of rats after RE establishment and ATL III treatment in samples of a) sham group, b) RE group, c) ATL III (0.6 mg/kg), d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. B) H&E stained images of the sectioned esophagus tissues of rats after RE establishment and ATL III treatment. a) sham group, b) RE group, c) ATL III (0.6 mg/kg) d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after RE establishment and ATL III treatment. D) The graph indicates the gastric pH changes after RE establishment and ATL III treatment. *** indicates P < 0.001 vs. RE group. E) The graphs present the ROS and F) TBARS levels after various treatments of ATL-III group. *** indicates P < 0.001 vs. RE group .

Article Snippet: ATL III and 740 Y–P were obtained from Abmole Bioscience Inc. (Shanghai, China).

Techniques: Staining, Marker

ATL III attenuates esophageal inflammation in RE rats. The graphs show the levels of various inflammatory indicators, A) IL-1β, B) IL-6, C) IL-8, and D) TNF-α. E) The Western blot analysis indicates the expression levels of various IL-1β, IL-6, IL-8, and TNF-α proteins against β-Actin as internal standard at the 2.4 mg/kg dose of ATL III. * indicates P < 0.05 vs. RE group, and *** represents P < 0.001.

Journal: Heliyon

Article Title: Atractylenolide III ameliorated reflux esophagitis via PI3K/AKT/NF-κB/iNOS pathway in rats

doi: 10.1016/j.heliyon.2023.e21224

Figure Lengend Snippet: ATL III attenuates esophageal inflammation in RE rats. The graphs show the levels of various inflammatory indicators, A) IL-1β, B) IL-6, C) IL-8, and D) TNF-α. E) The Western blot analysis indicates the expression levels of various IL-1β, IL-6, IL-8, and TNF-α proteins against β-Actin as internal standard at the 2.4 mg/kg dose of ATL III. * indicates P < 0.05 vs. RE group, and *** represents P < 0.001.

Article Snippet: ATL III and 740 Y–P were obtained from Abmole Bioscience Inc. (Shanghai, China).

Techniques: Western Blot, Expressing

ATL III inhibits PI3K/AKT/NF-κB/iNOS pathway. A) Images show the esophagus of rats after treatment with a) sham group, b) RE group, c) RE+2.4 mg/kg of ATL III, d) RE+2.4 mg/kg of ATL III +10 mg/kg of 740 Y–P. B) H&E stained images of the sectioned esophagus tissues of rats after treatment with a) sham group, b) RE group, c) RE+2.4 mg/kg ATL III, d) RE+2.4 mg/kg of ATL III +10 mg/kg of 740 Y–P. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. D) The graph signifies the gastric content pH after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. E) The image shows the ROS levels after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. F) The image shows the TBARS levels after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. G) The image shows the expression levels of various inflammatory indicators (TNF-α, IL-8, IL-6, and IL-1β) after treatment with ATL III + 10 mg/kg of 740 Y–P in RE rats. ** indicates P < 0.01 and *** represents P < 0.001 vs. RE. & presents P < 0.05 and &&& signifies P < 0.001 vs. RE + 2.4 mg/kg ATL III.

Journal: Heliyon

Article Title: Atractylenolide III ameliorated reflux esophagitis via PI3K/AKT/NF-κB/iNOS pathway in rats

doi: 10.1016/j.heliyon.2023.e21224

Figure Lengend Snippet: ATL III inhibits PI3K/AKT/NF-κB/iNOS pathway. A) Images show the esophagus of rats after treatment with a) sham group, b) RE group, c) RE+2.4 mg/kg of ATL III, d) RE+2.4 mg/kg of ATL III +10 mg/kg of 740 Y–P. B) H&E stained images of the sectioned esophagus tissues of rats after treatment with a) sham group, b) RE group, c) RE+2.4 mg/kg ATL III, d) RE+2.4 mg/kg of ATL III +10 mg/kg of 740 Y–P. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. D) The graph signifies the gastric content pH after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. E) The image shows the ROS levels after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. F) The image shows the TBARS levels after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. G) The image shows the expression levels of various inflammatory indicators (TNF-α, IL-8, IL-6, and IL-1β) after treatment with ATL III + 10 mg/kg of 740 Y–P in RE rats. ** indicates P < 0.01 and *** represents P < 0.001 vs. RE. & presents P < 0.05 and &&& signifies P < 0.001 vs. RE + 2.4 mg/kg ATL III.

Article Snippet: ATL III and 740 Y–P were obtained from Abmole Bioscience Inc. (Shanghai, China).

Techniques: Staining, Marker, Expressing

A)ATL III inhibits PI3K/AKT/NF-κB in the esophageal tissues of RE rats. The Western blot analysis indicates the expression levels of various p-PI3K, p -AKT, iNOS, and nuclear NF-κB and Laminin B1 proteins against β-Actin as internal standard at the 2.4 mg/kg dose of ATL III. B) The Western blot analysis indicates the expression levels of various p-PI3K, p -AKT, iNOS, and nuclear NF-κB and Laminin B1 proteins against β-Actin as internal standard after treated with the ATL III +740 Y–P.

Journal: Heliyon

Article Title: Atractylenolide III ameliorated reflux esophagitis via PI3K/AKT/NF-κB/iNOS pathway in rats

doi: 10.1016/j.heliyon.2023.e21224

Figure Lengend Snippet: A)ATL III inhibits PI3K/AKT/NF-κB in the esophageal tissues of RE rats. The Western blot analysis indicates the expression levels of various p-PI3K, p -AKT, iNOS, and nuclear NF-κB and Laminin B1 proteins against β-Actin as internal standard at the 2.4 mg/kg dose of ATL III. B) The Western blot analysis indicates the expression levels of various p-PI3K, p -AKT, iNOS, and nuclear NF-κB and Laminin B1 proteins against β-Actin as internal standard after treated with the ATL III +740 Y–P.

Article Snippet: ATL III and 740 Y–P were obtained from Abmole Bioscience Inc. (Shanghai, China).

Techniques: Western Blot, Expressing